Sugi Predict

Sugi Predict / Targets / HHAT

HHAT

Protein-cysteine N-palmitoyltransferase HHAT · Q5VTY9 · HHAT on Sugi Atlas →

3,166 patent compounds predicted against HHAT, 1,469 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3364044 SCHEMBL3364044 0.71 14/20
SCHEMBL2307643 SCHEMBL2307643 0.54 13/20
SCHEMBL2307614 SCHEMBL2307614 0.51 13/20
SCHEMBL2312509 SCHEMBL2312509 0.63 12/20
SCHEMBL2310357 SCHEMBL2310357 0.53 12/20
SCHEMBL2307314 SCHEMBL2307314 0.46 12/20
SCHEMBL2309722 SCHEMBL2309722 0.56 11/20
SCHEMBL2306967 SCHEMBL2306967 0.55 11/20
SCHEMBL2306165 SCHEMBL2306165 0.64 10/20
SCHEMBL2307619 SCHEMBL2307619 0.57 10/20
SCHEMBL2311653 SCHEMBL2311653 0.56 10/20
SCHEMBL2307660 SCHEMBL2307660 0.53 10/20
SCHEMBL2309069 SCHEMBL2309069 0.61 9/20
SCHEMBL2308216 SCHEMBL2308216 0.59 9/20
SCHEMBL2308965 SCHEMBL2308965 0.53 9/20
SCHEMBL2304886 SCHEMBL2304886 0.52 9/20
SCHEMBL2310228 SCHEMBL2310228 0.50 9/20
SCHEMBL2306122 SCHEMBL2306122 0.65 8/20
SCHEMBL2306208 SCHEMBL2306208 0.64 8/20
SCHEMBL2305413 SCHEMBL2305413 0.60 8/20

Clinical trials — most relevant to HHAT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) PHASE4COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension PHASE2NOT_YET_RECRUITING
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver PHASE2COMPLETED
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels PHASE1COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
De Novo Lipogenesis in Severity of NAFLD nanCOMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease nanNOT_YET_RECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Stearoyl-CoA Desaturase and Energy Metabolism in Humans nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Diabetic Cardiomyopathy and Heart Failure nanWITHDRAWN
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Acute Fatty Acid Intervention Study (AFAST) nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Omics-based Predictors of NAFLD/Potential NASH nanUNKNOWN
Gene Expression and Inflammation in Overweight Subjects nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HHAT binder may also engage these)

ProteinNameSimilarity
Q8BMT9 — 0.991 Q8BMT9 →
MBOAT7 Membrane-bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7 0.960 landscape →
Q0VCY6 — 0.958 Q0VCY6 →
Q8CHK3 — 0.958 Q8CHK3 →
B2LYG4 — 0.951 B2LYG4 →
PORCN Protein-serine O-palmitoleoyltransferase porcupine 0.951 landscape →
P59266 — 0.950 P59266 →
Q8N6M3 — 0.949 Q8N6M3 →
A4IFN5 — 0.949 A4IFN5 →
Q86WK9 — 0.939 Q86WK9 →
Q5H8A4 — 0.939 Q5H8A4 →
Q9JJJ7 — 0.936 Q9JJJ7 →
Q865K8 — 0.935 Q865K8 →
Q9QUK3 — 0.934 Q9QUK3 →
Q9BSA9 — 0.933 Q9BSA9 →
Q6PHN7 — 0.933 Q6PHN7 →
Q5JZQ7 — 0.933 Q5JZQ7 →
Q9UBY8 — 0.932 Q9UBY8 →
Q9JJQ0 — 0.932 Q9JJQ0 →
Q8TBR7 — 0.930 Q8TBR7 →
Q9D8B1 — 0.929 Q9D8B1 →
Q6AYM9 — 0.929 Q6AYM9 →
Q3T9M1 — 0.929 Q3T9M1 →
TMEM164 Transmembrane protein 164 0.928 landscape →
Q6AY05 — 0.928 Q6AY05 →
Q9CXY1 — 0.928 Q9CXY1 →
Q8NHX9 — 0.928 Q8NHX9 →
Q8MK44 — 0.927 Q8MK44 →
A6NFX1 — 0.927 A6NFX1 →
Q92521 — 0.927 Q92521 →